Vertex Pharmaceuticals Incorporated Share Price and Company Fundamentals

2.360 (0.808%)
52 week
176.36 - 301.8

Last traded: Last Friday at 8:00 PM

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Key Metrics

PE ratio


PB ratio


Dividend yield




Market cap


Enterprise value


Company profile

Industry / SectorBiotechnology / Healthcare
Full time employees3900
Mailing address50 Northern Avenue Boston MA 02210 United States
Phone / Fax617 341 6100 /


Dividend yield


Dividend amount


Payout ratio


Vertex Pharmaceuticals Incorporated paid $0.00 dividend and the ex-dividend date was .The dividend payout ratio is 0.00%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.VRTX dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.

VRTX's forward dividend amount is $ and the forward dividend yield is . A forward dividend yield is the percentage of a company's current stock price that it expects to pay out as dividends over a certain time period, generally 12 months. Forward dividend yields are generally used in circumstances where the yield is predictable based on past instances. If not, trailing yields, which indicate the same value over the previous 12 months, are used.

Company Executives

As of Aug 2022, following are the company executives and directors listed on Vertex Pharmaceuticals Incorporated.

NameTitleAgeTotal Pay
Dr. Jeffrey Marc Leiden M.D., Ph.D.Exec. Chairman65281.98k
Dr. Reshma Kewalramani FASN, M.D.CEO, Pres & Director484.27M
Mr. Charles F. Wagner Jr.Exec. VP & CFO531.85M
Mr. Stuart A. Arbuckle B.Sc.Exec. VP & COO552.56M
Dr. Ourania Tatsis Ph.D.Exec. VP and Chief Regulatory & Quality Officer501.33M
Ms. Kristen C. AmbroseChief Accounting Officer & SVP of Accounting, Tax, Treasury, Strategic Sourcing & Corp. Services44
Dr. David M. Altshuler M.D., Ph.D.Exec. VP of Global Research & Chief Scientific Officer56
Mr. Mike TirozziSVP and Chief Information & Data Officer
Mr. Michael PartridgeSr. VP of Investor Relations
Mr. Damian W. Wilmot Esq.Sr. VP, Chief Risk and Compliance Officer45

Profitability and management effectiveness

Profit margin


Operating margin


Return on assets


Return on equity


Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.

The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.

Valuation and Trading Info

The market capitalization of Vertex Pharmaceuticals Incorporated is and its enterprise value is .

The VRTX's stocks Beta value is 0.45 making it 55% less volatile compared to NASDAQ market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Frequently Asked Questions

1. What is Vertex Pharmaceuticals Incorporated's Stock Symbol?

Vertex Pharmaceuticals Incorporated trades on NASDAQ under the ticker symbol "VRTX".

2. What is Vertex Pharmaceuticals Incorporated's stock price today?

One share of VRTX stock can currently be purchased for approximately $294.52.

3. How can I contact Vertex Pharmaceuticals Incorporated?

Vertex Pharmaceuticals Incorporated's mailing address is 50 Northern Avenue Boston MA 02210 United States. The company can be reached via phone at 617 341 6100.

4. What is Vertex Pharmaceuticals Incorporated's official website?

The official website of Vertex Pharmaceuticals Incorporated is